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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S80Conclusions: The current study provides a comprehensive proﬁle of
cytokines, chemokines and growth factors present in the OA and the
healthy joint environment. Increased soluble mediators, such as IL-6, IP-10,
MDC and RANTES, indicate the involvement of a catabolic process in OA.
This biomarker proﬁle might be useful to distinguish OA patients from
healthy donors, however needs to be validated in future experiments.
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A NEW SANDWICH BIOMARKER ASSAY FOR CARTILAGE TYPE II
COLLAGEN CAN DISCRIMINATE BETWEEN NO OSTEOARTHRITIS (OA),
PRE-RADIOGRAPHIC AND RADIOGRAPHIC KNEE OA IN HUMAN URINE.
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Purpose: Molecular biomarkers, especially those that detect cleavage of
cartilage type II collagen, offer the potential to detect early pre-radio-
graphic osteoarthritis (PROA) and radiographic OA (ROA). Increased
type II collagen cleavage by collagenases is a well-established feature in
OA knee articular cartilage. Yet existing assays have exhibited limited
ability to discriminate between these patient populations and those
without OA. By focusing on a 45 mer collagenase-generated peptide of
type II collagen found in increased amounts in urine of OA patients
(Nemirovskiy et al, 2007), a new assay has been developed that can
discriminate knee PROA and knee ROA from subjects with no detectable
OA (NoOA) on magnetic resonance imaging (MRI). Initial encouraging
results are presented here.
Methods: The newly developed sandwich assay for urine (IB-C2C-
HUSATM) detects the type II collagen speciﬁc C-terminus of the 3/4 piece
generated by collagenase and an intrachain epitope within 45 residues of
this cleavage site. This was compared to an existing competitive inhibition
assay (C2C ELISA) that also detects this cleavage site neoepitope in type II
collagen alpha-chains and any other alpha-chain fragments containing this
neoepitope. Assay results were expressed as pg per mmol creatinine. Urine
samples from the population-based Model for the Diagnosis of Early Knee
Osteoarthritis (MoDEKO) cohort were analyzed. The unique MoDEKO
cohort consists of subjects with knee pain, age 40 to 79, classiﬁed based on
knee MRI and x-ray (34 NoOA; 120 PROA and 98 ROA_sample-weighted
counts). Data were analyzed for differences between OA subgroups using
descriptive statistics. Multinomial logistic regression analysis was per-
formed to evaluate the associations between biomarkers and radio-
graphically/MRI deﬁned OA subgroups vs. NoOA, reported as odds ratios
(ORs) and 95% conﬁdence intervals (CI) after log-transformation and
adjustment for age, gender and BMI. All analyses were sample-weighted.
Results: Results for the C2C ELISA inhibition assay revealed no ability to
discriminate between the different groups in urine (Fig.1). In contrast, the
IB-C2C-HUSATM sandwich assay revealed the presence of progressively
higher concentrations of the cleavage neoepitope in PROA and ROA groups
compared to the NoOA group (Fig.1). Multinomial logistic regression
results revealed that the new urine assay could signiﬁcantly predict the
three groups (overall p <0.001): OR 2.90 (95% CI 1.64, 5.13) for ROA vs.
NoOA, OR 1.55 (95% CI 0.95, 2.50) for PROA vs. NoOA and OR 1.88 (95% CI
1.27, 2.77) for ROA vs. PROA. Interestingly, this discrimination was often
stronger when urine data were not corrected for creatinine: OR 3.97 (2.03,
7.78) for ROA vs. NoOA ; OR 2.30 (1.22, 4.32) for PROA vs. NoOA and OR 1.73
(1.23, 2.43) for ROA vs. PROA.
Conclusions: Our results demonstrate the ability of this new urine-speciﬁc
sandwich assay to discriminate between NoOA, PROA and ROA in amanner
not previously possible with the original C2C inhibition assay. It also
provides further evidence to suggest that the 45mer alpha-chain fragment
of type II collagen, that contains the collagenase cleavage site, is generated
in increased amounts in knee OA and can be selectively detected in urine.
This new biomarker assay may be of value in studying disease onset,
progression and treatment in OA.Ă
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MEASUREMENTS OF URINARY COLL2-1NO2 IS PREDICTIF OF JOINT
SPACE NARROWING IN KNEE OSTEOARTHRITIS
Y. Henrotin 1, V. Kraus 2, K.D. Brandt 3, S.A. Mazzuca 3, J. Huebner 2,
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2Duke Univ. Med. Ctr., Durham, NC; 3Univ. Sch. of Med., Indianapolis, IN;
4Arlenda SA, Liège, Belgium; 5Artialis SA, Liège, BelgiumPurpose: To evaluate the predictive value of Coll2-1NO2, a biochemical
marker of inﬂammation-related cartilage degradation, for radiographic
knee osteoarthritis (OA) progression. Coll2-1NO2 [HRGY(NO2)PGLDG], is
the nitrated from of Coll2-1 (HRGYPGLDG), a denaturation epitope of the
type II collagen molecule.
Methods: Two OA populations were studied: population 1 was composed
by 135 obese men andwomen aged 45 to 64 years with mild andmoderate
knee OA (presence of osteophytes and a minimum joint space width  2
mm in themedial compartment); population 2 included 182 obesewomen
with unilateral radiographic knee OA (K&L II or III) aged 45 to 64 years from
the placebo arm of the doxycycline study (Brandt et al., 2004). For both
populations, quantitative estimates of changes in joint space width (JSW)
in the medial tibiofemoral compartment were obtained from ﬂuoroscop-
ically assisted semi-ﬂexed AP radiographs performed at baseline,16 and 30
months. The creatinine-adjusted urinary Coll2-1NO2 (uColl2-1NO2)
concentrationwas measured on samples obtained at baseline, after 16 and
30 months for the patients from population 1 and at baseline and after 6,
12, 18, 24 and 30 months for the patients from population 2. Patients
showing a decrease of JSW  0.5 mm over 30 months follow-up were
designated radiographic progressors. The comparison of progressor and
nonprogressor patients at inclusion was performed by an unpaired t-test.
The results were expressed as medians (minimum and maximum). The
ability of biomarker to predict radiographic progression of knee osteoar-
thritis was evaluated by logistic regression analysis. The covariates in the
model are uColl2-1NO2 at baseline and the change over 16 months of
uColl2-1NO2.
